Quick Win By The Algorithm

On April 6th, 2017, I Know First’s algorithm issued a bullish forecast for IMMU, with a signal of 102.77 and a predictability factor of 0.37. These three-month returns confirmed the algorithm’s prediction as the stock price went up by 41.33%.

Immunomedics is an innovative biopharmaceutical company that focuses on  cancer treatment and other serious diseases using antibody–based therapeutics. Immunomedics is headquartered in  Morris Plains, NJ.

During the three month period from April to July, IMMU continued the positive trend from the past two quarters. The latest quarterly report showed an attractive increase in revenue of 44.4%. In addition, brokerage houses have been suggesting investors to buy IMMU shares.

This positive trend persisting through these months is the result of a number of different factors: The conclusion of its licensing agreement with Seattle Genetics (SGEN) regarding the development of a highly important antibody-drug, a $125 million capital raise, and CEO Cynthia Sullivan stepping down.

Investors around the world took positive interest in the company when these news came out. As the investigation and development for the antibody-drug, known as IMMU-132, is a great opportunity for profit. Furthermore, The R&D for it has been awarded “breakthrough therapy” by the FDA, which quickens its development.

I Know First subscribers were sent this forecast on April 6th, 2017. 

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.